Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 130
Filter
1.
Medicina (Kaunas) ; 58(8)2022 Aug 05.
Article in English | MEDLINE | ID: mdl-36013527

ABSTRACT

Renal leukemic infiltration is uncommon in myeloid neoplasms, including myelodysplastic syndromes (MDS). A 76-year-old male patient was admitted to our hospital with complaints of fever and dyspnea. He was diagnosed with MDS with multilineage dysplasia and acute focal bacterial nephritis (AFBN) based on clinical, laboratory, and radiological investigations. Antibiotic treatment temporarily improved his condition, but the radiological image of AFBN remained. His condition gradually deteriorated into multiple organ failure, and he unfortunately died on the 31st day of hospitalization. Autopsy findings revealed significantly increased p53-positive blasts in the bone marrow and renal parenchyma overlapping AFBN, suggesting leukemic transformation and renal infiltration. This case emphasizes the need to review the diagnosis when antibiotic treatment is ineffective in MDS patients with AFBN.


Subject(s)
Myelodysplastic Syndromes , Nephritis , Aged , Anti-Bacterial Agents/therapeutic use , Autopsy , Humans , Leukemic Infiltration/drug therapy , Male , Myelodysplastic Syndromes/complications
2.
Pan Afr Med J ; 36: 142, 2020.
Article in English | MEDLINE | ID: mdl-32874406

ABSTRACT

Chronic myeloid leukemia (CML) is a myeloproliferative disorder associated with the Philadelphia chromosome t (9;22) and the BCR-ABL fusion gene. The condition is relatively rare, accounting for 2.0% to 3.0% of childhood leukemia cases. CML has historically been a triphasic disease. Most patients are diagnosed in chronic phase. Without treatment, it inevitably progresses into a more aggressive accelerated phase and blast crisis. Some proportion of CML cases of blastic transformation develop an extramedullary disease that involves rarely central nervous system. This report describe an extremely rare case of 13-year-old girl with CML and extramedullary blast crisis in the central nervous system. Treatment options and monitoring of disease response are discussed.


Subject(s)
Blast Crisis/diagnosis , Central Nervous System/pathology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Leukemic Infiltration/diagnosis , Adolescent , Algeria , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Blast Crisis/etiology , Blast Crisis/pathology , Central Nervous System/diagnostic imaging , Female , Humans , Imatinib Mesylate/administration & dosage , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Leukemic Infiltration/drug therapy , Leukemic Infiltration/pathology , Recurrence
4.
Cancer Metastasis Rev ; 38(4): 657-671, 2019 12.
Article in English | MEDLINE | ID: mdl-31820149

ABSTRACT

The cure rate of acute lymphoblastic leukemia (ALL), the commonest childhood cancer, has been sharply improved and reached almost 90% ever since the central nervous system (CNS)-directed therapy proposed in the 1960s. However, relapse, particularly in the central nervous system (CNS), is still a common cause of treatment failure. Up to now, the classic CNS-directed treatment for CNS leukemia (CNSL) has been aslant from cranial radiation to high-dose system chemotherapy plus intrathecal (IT) chemotherapy for the serious side effects of cranial radiation. The neurotoxic effects of chemotherapy and IT chemotherapy have been reported in recent years as well. For better prevention and treatment of CNSL, plenty of studies have tried to improve the detection sensitivity for CNSL and prevent CNSL from happening by targeting cytokines and chemokines which could be key factors for the traveling of ALL cells into the CNS. Other studies also have aimed to completely kill ALL cells (including dormant cells) in the CNS by promoting the entering of chemotherapy drugs into the CNS or targeting the components of the CNS niche which could be in favor of the survival of ALL cells in CNS. The aim of this review is to discuss the imperfection of current diagnostic methods and treatments for CNSL, as well as new attempts which could be significant for better elimination of CNSL.


Subject(s)
Central Nervous System/drug effects , Central Nervous System/radiation effects , Leukemic Infiltration/drug therapy , Leukemic Infiltration/radiotherapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Animals , Central Nervous System/pathology , Child , Cranial Irradiation , Humans , Injections, Spinal , Leukemic Infiltration/diagnosis , Leukemic Infiltration/pathology
7.
J Pediatr Ophthalmol Strabismus ; 55: e16-e19, 2018 Aug 29.
Article in English | MEDLINE | ID: mdl-30180238

ABSTRACT

The authors report a rare unilateral iris and ciliary body relapse in acute lymphoblastic leukemia. Ophthalmologic examination showed reduced visual acuity, pseudohypopyon, and iris irregularity. Ultrasound biomicroscopy and aqueous humor cytology confirmed leukemic infiltration. Lesions were treated with intravitreal methotrexate, which has not been described previously for acute lymphoblastic leukemia. [J Pediatr Ophthalmol Strabismus. 2018;55:e16-e19.].


Subject(s)
Ciliary Body/pathology , Iris/pathology , Leukemic Infiltration/drug therapy , Methotrexate/administration & dosage , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Antimetabolites, Antineoplastic/administration & dosage , Child , Female , Humans , Intravitreal Injections , Leukemic Infiltration/diagnosis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Slit Lamp Microscopy
10.
BMJ Case Rep ; 20182018 May 02.
Article in English | MEDLINE | ID: mdl-29724869

ABSTRACT

Leukaemia cutis or cutaneous infiltration of neoplastic myeloid or lymphoid cells is usually seen in the acute myelomonocytic and acute monocytic variants of acute myeloid leukaemia. Here, we report a case of acute promyelocytic leukaemia who achieved remission, presenting with skin lesions, the biopsy of which revealed leukaemia cutis, heralding the relapse of the disease. After establishing the diagnosis with bone marrow analysis, the patient was started on daunorubicin chemotherapy along with arsenic trioxide and all-trans retinoic acid. Afterwards, the skin lesions resolved, and the patient is planned for consolidation with bone marrow transplantation.


Subject(s)
Leukemia, Promyelocytic, Acute/pathology , Leukemic Infiltration/pathology , Skin/pathology , Antibiotics, Antineoplastic/administration & dosage , Antineoplastic Agents/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Arsenic Trioxide , Arsenicals/administration & dosage , Biopsy , Consolidation Chemotherapy , Daunorubicin/administration & dosage , Female , Humans , Leukemia, Promyelocytic, Acute/drug therapy , Leukemic Infiltration/drug therapy , Oxides/administration & dosage , Tretinoin/administration & dosage
11.
Spec Care Dentist ; 38(3): 160-162, 2018 May.
Article in English | MEDLINE | ID: mdl-29645289

ABSTRACT

Leukemic infiltration of the gingival tissue associated or not with gingival enlargement may be the first manifestation of acute leukemia, despite being rarely reported in the literature. A 10-year-old female patient presented with a 1-month history of an asymptomatic, firm, and pinkish-red generalized gingival overgrowth. There was no bone resorption. Incisional biopsy of the gingival tissue was performed, with histopathological examination revealing a diffuse and hypercellular infiltration of monocytoid cells. The patient was referred to a hematologist and underwent a bone marrow biopsy, which led to a conclusive diagnosis of acute myeloid leukemia. The patient was treated with chemotherapy and we observed regression of gingival enlargement after 4 weeks from the initial therapy.


Subject(s)
Gingival Overgrowth/pathology , Leukemia, Myeloid, Acute/diagnosis , Leukemic Infiltration/pathology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biopsy , Child , Female , Gingival Overgrowth/diagnostic imaging , Gingival Overgrowth/drug therapy , Humans , Leukemia, Myeloid, Acute/diagnostic imaging , Leukemia, Myeloid, Acute/drug therapy , Leukemic Infiltration/diagnostic imaging , Leukemic Infiltration/drug therapy , Radiography, Panoramic
14.
Blood ; 130(5): 643-654, 2017 08 03.
Article in English | MEDLINE | ID: mdl-28550041

ABSTRACT

In acute lymphoblastic leukemia (ALL), central nervous system (CNS) involvement is a major clinical concern. Despite nondetectable CNS leukemia in many cases, prophylactic CNS-directed conventional intrathecal chemotherapy is required for relapse-free survival, indicating subclinical CNS manifestation in most patients. However, CNS-directed therapy is associated with long-term sequelae, including neurocognitive deficits and secondary neoplasms. Therefore, molecular mechanisms and pathways mediating leukemia-cell entry into the CNS need to be understood to identify targets for prophylactic and therapeutic interventions and develop alternative CNS-directed treatment strategies. In this study, we analyzed leukemia-cell entry into the CNS using a primograft ALL mouse model. We found that primary ALL cells transplanted onto nonobese diabetic/severe combined immunodeficiency mice faithfully recapitulated clinical and pathological features of meningeal infiltration seen in patients with ALL. ALL cells that had entered the CNS and were infiltrating the meninges were characterized by high expression of vascular endothelial growth factor A (VEGF). Although cellular viability, growth, proliferation, and survival of ALL cells were found to be independent of VEGF, transendothelial migration through CNS microvascular endothelial cells was regulated by VEGF. The importance of VEGF produced by ALL cells in mediating leukemia-cell entry into the CNS and leptomeningeal infiltration was further demonstrated by specific reduction of CNS leukemia on in vivo VEGF capture by the anti-VEGF antibody bevacizumab. Thus, we identified a mechanism of ALL-cell entry into the CNS, which by targeting VEGF signaling may serve as a novel strategy to control CNS leukemia in patients, replacing conventional CNS-toxic treatment.


Subject(s)
Central Nervous System Neoplasms/metabolism , Leukemic Infiltration/metabolism , Neoplasm Proteins/metabolism , Neoplasms, Experimental/metabolism , Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism , Vascular Endothelial Growth Factor A/metabolism , Animals , Bevacizumab/pharmacology , Cell Survival/drug effects , Central Nervous System Neoplasms/drug therapy , Central Nervous System Neoplasms/pathology , Endothelial Cells/metabolism , Endothelial Cells/pathology , Heterografts , Humans , Leukemic Infiltration/drug therapy , Leukemic Infiltration/pathology , Mice , Mice, Inbred NOD , Mice, SCID , Neoplasm Proteins/antagonists & inhibitors , Neoplasm Transplantation , Neoplasms, Experimental/drug therapy , Neoplasms, Experimental/pathology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Transendothelial and Transepithelial Migration/drug effects , Vascular Endothelial Growth Factor A/antagonists & inhibitors
16.
Arch Soc Esp Oftalmol ; 92(3): 145-148, 2017 Mar.
Article in English, Spanish | MEDLINE | ID: mdl-27402450

ABSTRACT

CLINICAL CASE: A 43-year-old woman in remission from T- cell acute lymphoblastic leukaemia was referred to our hospital with suspected leukaemic retinitis. The funduscopic examination of her left eye revealed multifocal yellow-white peripheral retinitis and retinal haemorrhage. The patient was treated for cytomegalovirus retinitis after an extended haematological investigation showed no abnormalities. Initial improvement was followed by papillitis in the left eye and motility restriction in the right eye. Magnetic resonance and lumbar puncture confirmed leukaemia relapse. Specific treatment was initiated with complete resolution. DISCUSSION: Ocular involvement may precede haematological leukaemia relapse. Physicians should be alerted when ocular symptoms appear in these cases.


Subject(s)
Cytomegalovirus Retinitis/etiology , Leukemic Infiltration , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/complications , Retina/pathology , Adult , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Combined Modality Therapy , Cytarabine/administration & dosage , Female , Granulocyte Colony-Stimulating Factor/administration & dosage , Humans , Idarubicin/administration & dosage , Leukemic Infiltration/drug therapy , Leukemic Infiltration/radiotherapy , Papilledema/etiology , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/pathology , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/radiotherapy , Recurrence , Retinal Hemorrhage/etiology , Vidarabine/administration & dosage , Vidarabine/analogs & derivatives
18.
Int J Hematol ; 105(3): 335-340, 2017 Mar.
Article in English | MEDLINE | ID: mdl-27848186

ABSTRACT

Dasatinib, a second-generation tyrosine kinase inhibitor, is a highly effective treatment for Bcr-Abl-positive leukemia. However, the mechanism by which dasatinib induces cell death is unclear, particularly in vivo. Autophagy is a lysosomal degradation mechanism essential for cell survival and differentiation. Autophagy also protects cells from the effects of drugs, including those used to treat leukemia. Here, we report that dasatinib induces autophagy in Bcr-Abl-positive leukemia cell lines and further show the induction of autophagy in an immunodeficient mouse model of human Bcr-Abl-positive leukemia with central nervous system (CNS) infiltration. Autophagy was induced in bone marrow (BM) as well as cerebrospinal fluid (CSF). This study is the first to show that autophagy induction is one of the mechanisms underlying cell death in leukemic cells that infiltrate the CNS. Thus, autophagy may represent a novel therapeutic target for the treatment of Bcr-Abl leukemia with CNS infiltration.


Subject(s)
Autophagy/drug effects , Dasatinib/pharmacology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Animals , Bone Marrow/pathology , Cell Line, Tumor , Central Nervous System/pathology , Cerebrospinal Fluid , Dasatinib/therapeutic use , Disease Models, Animal , Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Leukemic Infiltration/drug therapy , Mice
19.
An. bras. dermatol ; 91(5,supl.1): 72-75, Sept.-Oct. 2016. graf
Article in English | LILACS | ID: biblio-837930

ABSTRACT

Abstract Wolf's isotopic response designates the appearance of two subsequent unrelated dermatoses in the same anatomic location. We report the case of a 51-year-old man with a medical history of chronic lymphocytic leukemia without known extra-hematopoietic involvement. The patient developed a disseminated papulo-vesiculous eruption, diagnosed as varicella. Few days after recovering, an erythematous and violaceous papular dermatosis with histopathological examination compatible with leukemic infiltration appeared on the scars of previous herpetic lesions. Complete remission was obtained under systemic corticotherapy, without cutaneous recurrence or blastic transformation. Wolf's isotopic response is attributed to a localized immunologic imbalance following a certain stimulus. In this patient, herpetic infection acted as a local spur for inaugural cutaneous leukemic infiltration, with no impact on the prognosis for the underlying disease.


Subject(s)
Humans , Male , Middle Aged , Skin/pathology , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Chickenpox/pathology , Skin Diseases, Viral/pathology , Leukemic Infiltration/pathology , Immunohistochemistry , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Chickenpox/drug therapy , Treatment Outcome , Skin Diseases, Viral/drug therapy , Leukemic Infiltration/drug therapy , Dermis/pathology , Herpes Zoster/pathology
20.
J Neuroimmunol ; 298: 9-15, 2016 09 15.
Article in English | MEDLINE | ID: mdl-27609269

ABSTRACT

Though several functional properties of laquinimod have been identified, our understanding of the underlying mechanisms is still incomplete. Since the compound elicits similar immunomodulatory effects to ligands of the aryl hydrocarbon receptor (AhR), we compared the efficacy of laquinimod in experimental autoimmune encephalomyelitis (EAE)-afflicted wild-type and AhR-deficient mice. Laquinimod failed to ameliorate clinical symptoms and leukocyte infiltration in AhR-deficient mice; however, treatment exerted neuroprotection by elevation of brain-derived neurotrophic factor (BDNF) independent of genetic profile. Thus, our data identify the AhR pathway in these mutant mice as crucial for the immunomodulatory, but not neuroprotective, efficacy of laquinimod in EAE.


Subject(s)
Demyelinating Autoimmune Diseases, CNS/drug therapy , Demyelinating Autoimmune Diseases, CNS/immunology , Immunologic Factors/therapeutic use , Quinolones/therapeutic use , Receptors, Aryl Hydrocarbon/metabolism , Analysis of Variance , Animals , Axons/drug effects , Axons/pathology , Brain-Derived Neurotrophic Factor/genetics , Brain-Derived Neurotrophic Factor/metabolism , CD3 Complex/metabolism , Demyelinating Autoimmune Diseases, CNS/chemically induced , Disease Models, Animal , Gene Expression Regulation/drug effects , Gene Expression Regulation/genetics , Leukemic Infiltration/drug therapy , Mice, Inbred C57BL , Mice, Knockout , Myelin-Oligodendrocyte Glycoprotein/toxicity , Peptide Fragments/toxicity , RNA, Messenger/metabolism , Rats , Receptors, Aryl Hydrocarbon/genetics , Spinal Cord/pathology , T-Lymphocytes/drug effects , White Matter/drug effects , White Matter/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...